National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

HIV/AIDS
 Understanding
 Research
  Research Program
  Basic Research
  Epidemiology
  Prevention
  Therapeutics
  Vaccines
  Clinical Research
  Advisory Groups and Committees
  Partners and Collaborators
  Funding Opportunities
  Scientific Meetings, Workshops and Events


HIV/AIDS

Epidemiology

Identifying and understanding the risk factors associated with HIV acquisition and transmission, and the development and progression of AIDS in men, women, and adolescents are critical aspects in the fight against this disease. Using epidemiological methods, NIAID-supported investigators are able to address key scientific questions by studying and comparing the effects of HIV in different human populations. Scientific findings gathered from these epidemiological studies help to provide insight on how to prevent the spread of HIV and also improve the quality of life for those already infected.  

One major area of investigation involves studying the patterns of use and the efficacy/effectiveness of therapies in clinical trials and in cohort studies. The dramatic impact of highly active antiretroviral therapy (HAART) on HIV infection has prompted researchers to study the long-term clinical course of HIV infection in persons using HAART. While to date there have been no signs of a decrease in the effectiveness of HAART therapy, widespread drug resistance remains a concern. Furthermore, as people living with HIV continue to live longer, many of these immunocompromised individuals, who will naturally have a higher prevalence of other disease risk factors due to age, may develop other life threatening morbidities, such as heart disease or cancer, at a younger age than their HIV-negative peers. These types of scientific questions are now being investigated through epidemiological research.  The current goals of NIAID's epidemiological research include: 

  • Identifying the proportion of the population affected by HIV and the rate at which new infections are occurring
  • Describing the changing manifestations of the clinical and laboratory course of HIV infection, the changing frequency with which various complications occur, and the impact of therapy on HIV-related survival and clinical outcomes
  • Investigating the clinical course of HIV infection among persons with other co-morbidities to better understand the natural and treated history of the disease in those with other chronic conditions
  • Evaluating the patterns of adherence to HAART in populations around the world, the predictors of disease progression, and the efficacy of HAART in populations exposed to a variety of other concomitant infections and under nutritional and other health stressors
  • Studying the biological, clinical, and epidemiological characteristics of people who are at high risk for HIV infection but do not become infected and those who are long-term non-progressors

Additional Information

Highlights

NIAID Media Availability: NIAID Director Fauci Discusses Compelling Scientific Challenges in HIV/AIDS Research—Nov. 3, 2009

Statement of Anthony S. Fauci, M.D., on National Latino AIDS Awareness Day, Oct. 15, 2009—Oct. 15, 2009

National Gay Men’s HIV/AIDS Awareness Day, September 27, 2009—Sept. 25, 2009

See Also

  • Division of AIDS
  • Vaccine Research Center
  • HIV/AIDS Publications
  • HIV/AIDS News Releases
  • Global Research, Africa
  • Selected NIAID Science Advances, 2007-2008 (PDF)
  • Vaccines
  • NIAID Funding News

  • Highlights

    NIAID Media Availability: NIAID Director Fauci Discusses Compelling Scientific Challenges in HIV/AIDS Research—Nov. 3, 2009

    Statement of Anthony S. Fauci, M.D., on National Latino AIDS Awareness Day, Oct. 15, 2009—Oct. 15, 2009

    National Gay Men’s HIV/AIDS Awareness Day, September 27, 2009—Sept. 25, 2009

    See Also

  • Division of AIDS
  • Vaccine Research Center
  • HIV/AIDS Publications
  • HIV/AIDS News Releases
  • Global Research, Africa
  • Selected NIAID Science Advances, 2007-2008 (PDF)
  • Vaccines
  • NIAID Funding News